Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Chemocentryx Inc (CCXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 462,349
  • Shares Outstanding, K 50,530
  • Annual Sales, $ 82,500 K
  • Annual Income, $ 17,859 K
  • 36-Month Beta 1.78
  • Price/Sales 5.71
  • Price/Cash Flow 24.99
  • Price/Book 21.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.32
  • Prior Year 0.80
  • Growth Rate Est. (year over year) -133.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.07 +0.88%
on 11/14/18
12.07 -24.19%
on 11/07/18
-1.09 (-10.64%)
since 10/12/18
3-Month
9.07 +0.88%
on 11/14/18
13.50 -32.22%
on 09/05/18
-2.14 (-18.95%)
since 08/14/18
52-Week
5.42 +68.82%
on 12/27/17
15.08 -39.32%
on 03/21/18
+1.94 (+26.91%)
since 11/14/17

Most Recent Stories

More News
ChemoCentryx (CCXI) Reports Q3 Loss, Lags Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 12.00% and -22.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CCXI : 9.15 (-1.82%)
ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights

-- Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to launch in late 2018 -

CCXI : 9.15 (-1.82%)
ChemoCentryx to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018. ChemoCentryx executive management...

CCXI : 9.15 (-1.82%)
Earnings Preview: ChemoCentryx (CCXI) Q3 Earnings Expected to Decline

ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CCXI : 9.15 (-1.82%)
Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)

-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ADVOCATE Phase III Pivotal Trial in ANCA-Associated Vasculitis --

CCXI : 9.15 (-1.82%)
Analysis: Positioning to Benefit within ChemoCentryx, Armstrong Flooring, Kornit Digital, NewLink Genetics, Silvercorp Metals, and Halcon Resources -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ChemoCentryx, Inc. (NASDAQ:CCXI),...

HK : 2.95 (-2.32%)
AFI : 14.83 (-2.56%)
SVM : 1.88 (-8.29%)
CCXI : 9.15 (-1.82%)
KRNT : 22.40 (+4.67%)
NLNK : 1.86 (-3.12%)
ChemoCentryx Announces Proposed Public Offering of Common Stock

ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock. In connection with this offering, ChemoCentryx plans to grant...

JPM : 107.33 (-2.06%)
CCXI : 9.15 (-1.82%)
ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday...

CCXI : 9.15 (-1.82%)
VIFOR PHARMA GROUP INCREASES EQUITY INVESTMENT IN CHEMOCENTRYX

Vifor Pharma Ltd. / VIFOR PHARMA GROUP INCREASES EQUITY INVESTMENT IN CHEMOCENTRYX . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement....

GNHAF : 151.1000 (-15.30%)
CCXI : 9.15 (-1.82%)
ChemoCentryx to Present at Two Upcoming Investor Conferences

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September:

CCXI : 9.15 (-1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CCXI with:

Business Summary

ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.

See More

Key Turning Points

2nd Resistance Point 9.58
1st Resistance Point 9.36
Last Price 9.15
1st Support Level 9.00
2nd Support Level 8.86

See More

52-Week High 15.08
Fibonacci 61.8% 11.39
Fibonacci 50% 10.25
Last Price 9.15
Fibonacci 38.2% 9.11
52-Week Low 5.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar